Breaking AI & Tech News Analyzed

The LeadA daily pill has shown remarkable results in doubling survival time for patients with pancreatic cancer, the world's deadliest form of the disease. According to clinical trial results presented at the American Society of Clinical Oncology's annual meeting, this breakthrough treatment represents a potential revolution in how we approach a cancer that has seen limited progress for decades.The Breakthrough Drug: DaraxonrasibThe drug in question, daraxonrasib, works by targeting a protein called Kras that fuels nearly all pancreatic cancers. This mechanism represents a significant advancement in treatment strategy, as Kras has been notoriously difficult to target effectively. The drug functions as a Ras(On) multi-selective inhibitor, capable of turning off the Kras protein to stop cancer growth regardless of which variant is present.Impressive Trial ResultsIn the clinical trial involving 500 patients with advanced pancreatic cancer, the results were striking. Those who took daraxonrasib lived an average of 13.2 months, compared to just 6.6 to 6.7 months for patients who received chemotherapy. This represents a near doubling of survival time, with the added benefit of fewer side effects compared to traditional chemotherapy treatments.Industry Impact and Expert ReactionsThe findings have been hailed as a "gamechanger" and "grand slam" by experts in the field. Dr. Rachna Shroff, chief of oncology at the University of Arizona Cancer Center, described the results as "landscape-changing" and "unprecedented survival." When she first read the trial results, conducted by researchers at the Dana-Farber Cancer Institute in Boston, she wept, noting the profound impact this could have on patients after 16 years of treating pancreatic cancer.Dr. Julie Gralow, Asco's chief medical officer, echoed these sentiments, calling the study a "home run" and suggesting it was actually a "grand slam" in terms of its significance.The Ras RevolutionOver 90% of patients with the most common form of pancreatic cancer, pancreatic ductal adenocarcinoma (mPDAC), have a mutation in the Kras gene. This discovery has long been considered the "holy grail" in cancer research, particularly for pancreatic cancer where the mutation is nearly ubiquitous and an early driver of cancer growth.Paula Hanford, chief executive of UK-based Pancreatic Cancer Action, called this one of the most significant developments in treatment she had ever seen. Similarly, Anna Jewell, director of services, research and innovation at Pancreatic Cancer UK, described the results as "exciting," noting that the drug gives patients "months more precious time with their loved ones."Future Outlook and ApplicationsThe success of daraxonrasib opens doors for similar treatments targeting Ras genes in other cancers. Experts at the conference noted that because Ras genes fuel various types of cancer, there is hope for breakthroughs in treating lung and colon cancers as well, with similar drugs already in development for these conditions.However, challenges remain in ensuring these promising treatments become widely available to patients. As Jewell pointed out, tragically half of all people with pancreatic cancer die within just three months of diagnosis, making the rapid implementation of such treatments crucial.

The Landmark Broadcasting Deal CBS Sports has secured a four-year deal to broadcast the Women’s Super League (WSL) live in the US, starting from the next season and running until the end of the 2029-30 campaign. This deal represents a significant increase in valuation, potentially bringing in a fourfold increase in revenue for the WSL compared to previous seasons. Broadcasting Details Under the new agreement, the Paramount+ streaming service will air 183 WSL matches per season. Additionally, the CBS Sports Network will show one live match per week, with select matches also airing on the CBS Sports Golazo Network. This deal was negotiated by IMG, the international media rights representative for WSL Football. The Impact on Women's Football This deal marks a new record high for a US broadcasting agreement in the WSL. CBS Sports already holds rights to other women’s leagues, including the NWSL and the Women’s Champions League. The network had previously held WSL rights during the 2023-24 season. Zarah Al-Kudcy, WSL Football’s chief revenue officer, expressed excitement about welcoming CBS Sports back, highlighting their commitment to women’s football and their extensive talent roster. The Future of WSL Broadcasting The deal was finalized much earlier than previous agreements, which were typically announced shortly before the start of the season. This early conclusion brings stability and excitement ahead of the next WSL season in September. The partnership also comes as several WSL players have been named to the US women’s national team roster, further boosting the league’s profile.

The Schreiber family, presiding over a nationwide commercial portfolio via the Midos Group, is at the center of a growing controversy involving two distinct business models: aggressive tax avoidance and the profiteering from the UK's housing crisis. The Dual Nature of the Schreiber Business Empire The investigation reveals a complex web of family-owned entities that appear to operate on opposite ends of the social spectrum. On one side, the Midos Group is accused of exploiting a controversial tax scheme to avoid business rates on empty commercial properties. On the other, a similarly named but ostensibly separate entity, Midos Management Co, is profiting from the UK's chronic shortage of social housing by arranging temporary accommodation for homeless residents. Midos Group: Accused of using the 'faith room' scheme to avoid rates on empty units. Midos Management Co: Collecting fees for arranging temporary accommodation for councils. Key Figures: David Schreiber (Midos Group) and Elizabeth Endzweig (Midos Management Co). Financial Impact of the 'Faith Room' Tax Loophole The core of the tax avoidance allegations centers on a provision that exempts property owners from paying business rates if the space is made available for religious worship. The 'faith room' scheme, marketed by Verity, allegedly involves minimal activity—such as placing a notice and a staff member reading scripture—to create the appearance of worship. Total Savings: Landlords have saved at least £18m through this scheme. Specific Case: Dover District Council is suing for £1.7m of unpaid tax. Properties Involved: Discovery Park in Kent and a disused pub in Clapham, London. Profiting from the Homelessness Crisis While the family allegedly avoids taxes on empty buildings, they are simultaneously capitalizing on the housing emergency. Midos Management Co acts as an intermediary, matching councils with private landlords to house homeless residents. Despite claims of separation, evidence suggests significant overlap between the two entities. Revenue Collected: At least £43m collected on behalf of landlords since 2019. Client Base: Lambeth council and at least four other councils. Directorship Overlap: Elizabeth Endzweig, daughter of David Schreiber, is a co-director of multiple companies sharing the same address as Midos Group. The Future of UK Property Tax Compliance The revelations highlight a growing tension between private profit and public service obligations. With MPs and councils increasingly scrutinizing these arrangements, the 'faith room' exemption is likely to face tighter regulatory oversight. The case sets a precedent for how closely connected family businesses can be without violating anti-avoidance rules, potentially leading to stricter audits of corporate structures in the property sector.

The Concept of 'Mind Children' A few months ago, an AI researcher from Europe attended a dinner party in Silicon Valley. During one of the many courses, the host addressed his guests, all of whom worked in AI. The researcher paraphrased his message like this: “Isn’t it amazing that we are the last generation of humans who will need to think about procreating biologically? We were lucky enough to be born at a time where we can simply upload our consciousnesses instead.” The Book That Sparked the Conversation The book in question was Hans Moravec’s Mind Children: The Future of Robot and Human Intelligence, which was first published in 1988, and which at the time, according to economist and futurist Robin Hanson of George Mason University, caused a big splash in a small pond – the community of robotics and machine-learning experts to which Moravec belonged. The Data Analysis Moravec’s book is more philosophical treatise than technological manual, but the central idea is that cultural evolution has long since taken over from biological evolution as the most powerful force shaping humanity. The logical extrapolation of this is that the information that encodes our future selves would soon be packed into hardware and software rather than DNA. The Impact Analysis Angela Aristidou, who studies the real-life deployment of AI at University College London, is not surprised that Moravec’s book is enjoying a revival. She says that what in 1988 might have read like science fiction – and still might to most of us – looks eminently realisable to those in the know. The Prediction Hanson shares his conviction that the revolution is inevitable, as soon as AI attains something experts agree to call human-level intelligence. “We are going to generate an explosion of things like us in the future, who will be different from us in many ways,” Hanson says. “To the extent that they have minds somewhat like ours, they are our mind children.”

The Architecture of an African GiantIn less than two decades, Morocco has redefined African football, evolving from a team frequently eliminated in group stages to a global powerhouse ranked in the top 10 of the FIFA men’s rankings. This meteoric rise is not accidental but the result of a long-term national project initiated by King Mohammed VI in 2008.The success is built on three distinct pillars: good governance, financial investment, and competent human resources. The first step involved creating a national department for financial control to professionalise the federation's structure. This was followed by a massive infrastructure overhaul, including the construction of thousands of 'proximity fields' for mass participation and the Mohammed VI Complex in Maamoura, a technical center often compared to France's elite Clairefontaine academy.A Trophy Cabinet OverflowingThe impact of this strategy is evident in the sheer volume of recent accolades. The Atlas Lions have dominated across every age group, securing titles that span senior, youth, and women's football:2025 AFCON Champions (after Senegal were stripped of the title)2025 WAFCON Finalists2025 FIFA Arab Cup Champions2025 African Nations Championship (CHAN) Champions2025 U-20 FIFA World Cup Champions2025 U-17 AFCON Champions2024 Olympic Men’s Bronze Medallist2024 Futsal AFCON ChampionsThe Diaspora Strategy and Infrastructure BoomA critical factor in Morocco's ascent is the reform of national eligibility rules, which opened the door to players from the European diaspora. This strategy has attracted stars like Hakim Ziyech, Nordin Amrabat, and Brahim Diaz.The latest addition to this lineage is Ayyoub Bouaddi, an 18-year-old Lille midfielder. Despite interest from Zinedine Zidane and the French national team, Bouaddi chose to represent Morocco, highlighting the magnetic pull of the national project. The Mohammed VI Complex has already produced top talent, including Nayef Aguerd, Azzedine Ounahi, and Youssef En-Nesyri.Navigating the 2026 World Cup and the 2030 DreamWith high expectations for the 2026 World Cup in the USA, Canada, and Mexico, Morocco faces a transitional period following the resignation of coach Walid Regragui after the controversial 2025 AFCON final. The federation has appointed Mohamed Ouahbi, who led the youth team to the U-20 World Cup title.While Ouahbi’s more adventurous style differs from Regragui’s pragmatic resilience, the foundation is solid. The world views Morocco as a credible contender, but the team understands that the 2026 tournament is merely a milestone. With Morocco set to co-host the 2030 World Cup alongside Spain and Portugal, the current success is viewed as the acceleration of a broader national development agenda.

The Call for Tax Cuts Wes Streeting has called for national insurance tax cuts for businesses, and for the government to drill for oil and gas in the North Sea. The former health secretary and Labour leadership candidate told the Sunday Times there should be a “targeted reduction” of employers’ national insurance contribution as a way to “actively incentivise” hiring, particularly of young people. The Impact of National Insurance Rate Increase In 2024, the rate of national insurance paid by employers was increased from 13.8% on each employee’s salary to 15%. The starting threshold it applied to was lowered from £9,100 to £5,000. The measure aimed to raise £25bn a year, but businesses said it disincentivised hiring lower-paid and part-time staff. Youth Unemployment Concerns A report this week by the former cabinet minister Alan Milburn said a lack of hospitality jobs was contributing to high youth unemployment in Britain. It pointed to a halving of vacancies in the hospitality industry over the past four years alone. Analysis shows Britain has the third-highest rate of 16- to 24-year-olds who are not earning or learning among rich European countries. The Government's Response Pat McFadden, the work and pensions secretary, suggested he disagreed with this view. Speaking on Sky News on Sunday morning, he defended the government’s record, saying that businesses already did not have to pay employers’ national insurance for workers under 21. The Future of North Sea Drilling There has been a debate within Labour about whether to grant drilling consents for the giant oil and gas fields Rosebank and Jackdaw. Though there was a commitment not to give out any more licences for fossil fuels in Labour’s manifesto, there is a loophole that could be exploited; Rosebank and Jackdaw were given exploration licences by the previous Conservative government. They just need consent to drill. Ed Miliband's Decision Ed Miliband, the energy secretary, is due to make a decision on these oil and gas fields in coming weeks. He, along with the North Sea Transition Authority, have to decide whether the drilling would be consistent with the UK’s climate commitments.

The Connection to Nature As a recent study revealed almost half of UK adults now spend less than three hours a week in natural settings such as gardens, parks, fields or woods, we asked readers to tell us about what being outside means to them. Personal Stories of Healing The replies – heartfelt and passionate – came flooding in, with some admitting they just did not have the words to say how important it is. “It’s my happy place, my therapy and a reason to slow down and pause during my busy week,” wrote Hannah Powell from Perrywood garden centres. “I HAVE to look at plants every day. I notice every change in the garden. I sit facing the garden for my breakfast. I look out for nature on the way to work (recently seeing a little owl, red kites, foxes, hares, and more). It helped me get better when I had burnout and FND in London. I wouldn’t (couldn’t) be without it.” The Science Behind Nature's Benefits David Lynch esaid about his love of being outside. “Anxiety levels drop, all worldly concerns are put in perspective and [I] feel younger.” He agreed with others that there was plenty of recent science explaining the health benefits, but added: “I also read about ancient wisdom of Buddhism, which advocates solitary time in nature. All sources uphold the truth that better connection with nature brings better self-awareness and increased sensitivity to the needs of our ecosystem, plus better connection with each other.” The Impact on Mental Health Isabel Romaniw, who is working towards becoming a forest bathing guide, wrote passionately about the basic human need to be outside and to connect with nature. “We are animal, a simultaneously ordinary and yet utterly remarkable part of the great, miraculous tapestry of life on Earth. We have done much to shape our world and influence the fates of almost all other species we share our world with, but we must remember that we are but a tiny chapter, perhaps a footnote, in the ongoing story of the universe, in order to start to heal the damage and repair our relationships with ourselves, with each other, with our other-than-human kin, and with our one precious home.” For Romaniw, as for many others, our disconnection with nature is closely linked to “the worsening physical, mental and spiritual health crises that seem to be going on”. Cherished Memories of Nature Many of you had wonderful memories of times outside. “I was a sickly, pasty, shy, anxious kid,” wrote Mat Jordan. “In the early 70s my parents couldn’t afford to take us to the seaside one year so we went camping in the Peak District instead. It was a revelation. I absolutely loved it. The landscape and dry-stone walls of the white peak are still a favourite, although I spent some years in my 20s living in the Lake District too. One of my favourite memories is driving out of Sheffield into the Peaks with my then baby son to get him to fall asleep and still being awe-struck at the beauty on our doorstep.”

Day eight of the 2026 French Open at Roland‑Garros kicked off with a marquee clash between four‑time champion Iga Swiatek and rising talent Marta Kostyuk, alongside a host of other high‑stakes matches that could reshape the second week.Swiatek Takes on Kostyuk in a Potential ClassicThe opening encounter pits the defending champion, seeded #1, against the Ukrainian prodigy, seeded #12. Both players have displayed a blend of power and finesse throughout the tournament, setting the stage for a match that could define the women's title race.Seedings and Rankings Highlight the StakesIga Swiatek – World No. 1, French Open champion 2022‑2025.Marta Kostyuk – World No. 12, semifinalist in 2025.Jil Teichmann vs Mirra Andreeva – both ranked inside the top 30.Andrey Rublev – former top‑5, seeking a deep run after early exits by Djokovic, Alcaraz and Sinner.Implications for the Women’s Draw and Emerging ContendersA Swiatek victory would reinforce her dominance and likely secure a top‑seeded path to the final. A Kostyuk upset could open the draw for players like Elina Svitolina and Belinda Bencic, who are already positioned as dark horses.What to Watch in the Remainder of Day EightHow qualifier Wang Xiyu adapts to the clay after a surprise run.The performance of Jodár against Pedro Carreño Busta (men’s match).Whether Andrey Rublev can capitalize on the absence of the “Big Three”.

The Lead: Unprecedented Cancer Treatment SuccessDoctors have hailed "unprecedented" trial results that show a triple-action cancer jab can eradicate entire tumours in patients. In an international trial spanning 11 countries, the injection was offered to patients whose cancer had spread or come back and whose disease had failed to respond to other treatments.The Breakthrough: Amivantamab's Triple-Action ApproachThe jab, called amivantamab, shrank the tumours of more than a third of patients, with dramatic changes seen within weeks. In 15 of them, doctors found the drug had melted away their tumours altogether.The smart jab targets cancer in three ways. It blocks both EGFR (epidermal growth factor receptor), a protein that helps tumours grow, and MET, a pathway that cancer cells often use to escape treatment. It also helps activate the immune system to attack the tumour.The Clinical Trial Data: Impressive Response RatesIn the trial, 102 patients with head and neck cancer, the world's sixth most common cancer, were given the jab. Tumours shrank or disappeared completely in 43 patients, including 28 whose tumours shrank significantly and 15 who saw them eradicated entirely.Patients receiving amivantamab lived for a median of 12.5 months overall after starting treatment, despite having a form of cancer with very poor outcomes, once standard treatments stop working.The Impact Analysis: New Hope for Treatment-Resistant CancersKevin Harrington, professor in biological cancer therapies at the Institute of Cancer Research, London (ICR), said: "These are unprecedentedly strong responses in patients whose disease has become resistant to both chemotherapy and immunotherapy. This is a group of patients for whom treatment options are extremely limited, so seeing this level of benefit is very striking."Researchers also highlighted that the trial focused on people with head and neck cancers that did not include those with human papillomavirus (HPV) positive oropharyngeal squamous cell carcinoma. That is particularly significant, they said, since head and neck cancers not caused by HPV are usually harder to treat, making progress in this group hugely important.The Patient Experience: Transforming Quality of LifeOne of the first patients to benefit was Carl Walsh, 56, who was diagnosed with tongue cancer in May 2024 and joined the OrigAMI-4 trial at the Royal Marsden in July 2025. "I was initially treated with both chemotherapy and immunotherapy, which unfortunately were not successful," he said. "At that point, I was recommended for the OrigAMI-4 trial. I'm now on my 17th cycle of treatment and I'm very pleased with the progress so far."Unlike many cancer treatments, amivantamab is given as a tiny jab under the skin rather than via an intravenous drip, making treatment quicker and more convenient for patients and much easier to deliver in outpatient clinics.The Future Outlook: Expanding Treatment ApplicationsThe results will be presented on Sunday in Chicago at the world's largest cancer conference, the annual meeting of the American Society of Clinical Oncology (Asco).Amivantamab, developed by Johnson & Johnson, is now being evaluated in about 60 clinical trials, primarily for lung cancer, but also for colorectal, brain and gastric cancers.Prof Kristian Helin, the chief executive of the ICR, said: "This study demonstrates how the development of new treatments through rigorous cancer research may lead to meaningful advances, even for patients with very limited treatment options. Achieving this level of tumour response and encouraging survival outcomes in such a challenging-to-treat group represents a significant step forward."